• AI-Derived Prognostic Signature Enhances HCC Risk Stratifica

  2026-07-05

  This multi-center study introduces a consensus artificial intelligence-derived prognostic signature (CAIPS) that robustly predicts hepatocellular carcinoma (HCC) outcomes, outperforming traditional clinical parameters and published gene signatures. Integrating multi-omics data and functional validation, the study demonstrates CAIPS' utility in therapy optimization and highlights actionable molecular targets.

• GW4064 in FXR/TLR4 Signaling: A Bridge Between Metabolic and

  2026-07-04

  Explore the unique role of GW4064, a non-steroidal FXR agonist, in dissecting the FXR/TLR4 pathway and ferroptosis for advanced metabolic and fibrosis research. This article delivers in-depth mechanistic analysis and actionable protocol insights beyond standard metabolic assay workflows.

• Tetrahydromagnolol: Precision CB2 Agonist for Metastasis Mod

  2026-07-03

  Explore how Tetrahydromagnolol, a potent peripheral CB2 receptor agonist, enables advanced mechanistic studies in metastasis and inflammation. This article uniquely connects CB2 agonism with cytoskeletal signaling, providing practical insights for cannabinoid receptor research.

• EdU Cell Proliferation Kit (TMB): Precision S-Phase Detectio

  2026-07-03

  The EdU Cell Proliferation Kit (TMB) provides sensitive, direct detection of S-phase DNA synthesis using 5-ethynyl-2'-deoxyuridine incorporation. This robust assay, offered by APExBIO, enables accurate cell proliferation measurement and supports genotoxicity and pharmacodynamic studies with superior specificity compared to traditional methods.

• Rotigotine: Dopamine D2/D3 Receptor Agonist in PD Research

  2026-07-02

  Rotigotine stands out as a versatile dopamine D2/D3 receptor agonist, enabling robust modeling of Parkinson’s disease and related non-motor symptoms in both in vitro and in vivo settings. This guide details protocol refinements, troubleshooting strategies, and innovations inspired by recent mechanistic studies—empowering researchers to maximize assay reproducibility and translational impact.

• Tamsulosin (SKU C6445): Scenario-Based Solutions for Lab Ass

  2026-07-02

  This article provides practical, scenario-driven guidance for biomedical researchers using Tamsulosin (SKU C6445) to overcome common assay challenges in urological, GPCR signaling, and smooth muscle research. Drawing on meta-analytic evidence and validated product data, we address workflow compatibility, data interpretation, and vendor reliability, reinforcing the scientific rigor and reproducibility of APExBIO’s Tamsulosin.

• Cardiovascular Outcomes of Ertugliflozin in Type 2 Diabetes

  2026-07-01

  The VERTIS CV trial rigorously evaluated the cardiovascular safety and efficacy of ertugliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Results demonstrated noninferiority to placebo for major adverse cardiovascular events, shaping the evidence landscape for antihyperglycemic agents in high-risk populations.

• Purification and Kinetic Analysis of M. tuberculosis WecA

  2026-07-01

  This study presents a robust protocol for the over-expression, purification, and kinetic characterization of the Mycobacterium tuberculosis WecA membrane enzyme. The work enables mechanistic investigation and inhibitor screening, providing a foundation for anti-tuberculosis drug discovery targeting cell wall biosynthesis.

• Phosbind Acrylamide: Precision Phosphate-Binding Reagent for

  2026-06-30

  Phosbind Acrylamide is a specialized phosphate-binding reagent enabling high-resolution, antibody-free detection of protein phosphorylation by SDS-PAGE. It selectively interacts with phosphate groups, facilitating the analysis of protein phosphorylation states and mobility shifts. This product supports advanced research into phosphorylation-dependent signaling pathways.

• Vorinostat: HDAC Inhibition and Translational Oncology Strat

  2026-06-30

  This article explores the mechanistic underpinnings and strategic application of Vorinostat (SAHA) as a histone deacetylase inhibitor in translational oncology. Integrating recent mechanistic discoveries, including RNA Pol II-mediated cell death pathways, it offers actionable guidance for researchers seeking to leverage epigenetic modulation for next-generation cancer studies. Insights from comparative workflows and evidence-driven parameters equip translational teams to design robust, reproducible experiments with Vorinostat, advancing both biological understanding and therapeutic potential.

• Bifendate Reduces Hepatic Lipid Accumulation in Hypercholest

  2026-06-29

  This study demonstrates that Bifendate (DDB), a synthetic derivative of Schisandrin C, significantly lowers hepatic cholesterol and triglyceride levels in mouse models of diet-induced hypercholesterolemia. The findings clarify Bifendate’s hepatoprotective profile and highlight its utility as a lipid metabolism regulator in preclinical liver research.

• EZ Cap™ Human PTEN mRNA (ψUTP): Mechanisms & Research Impact

  2026-06-29

  EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA reagent engineered for enhanced stability and robust tumor suppressor gene expression. By incorporating pseudouridine and a Cap 1 structure, it delivers improved translational efficiency and immune evasion for advanced cancer research.

• XXLP Regulates NOX2/ROS/Mitochondria/NLRP3 Axis in Ulcerativ

  2026-06-28

  Xu Chunfu’s Modified Xianglian Pill (XXLP) demonstrates targeted regulation of the NOX2/ROS/mitochondria/NLRP3 axis, offering significant anti-inflammatory effects and gut microbiota modulation in experimental ulcerative colitis. The study integrates proteomics, molecular validation, and microbiome analysis, providing new mechanistic insights and evidence-based strategies for colitis management.

• Dextromethorphan Hydrobromide: Advanced Neuroprotection Stra

  2026-06-27

  Explore the unique mechanisms and advanced research applications of Dextromethorphan hydrobromide, a potent NMDA receptor antagonist. This article delivers in-depth scientific insights for neuroprotection research, with a distinct focus on assay optimization and translational relevance.

• Birinapant (TL32711): Applied Protocols for Apoptosis Resear

  2026-06-26

  Birinapant (TL32711) stands out as a high-affinity SMAC mimetic IAP antagonist, enabling precise apoptosis induction in challenging cancer models. This article translates recent advances, including biomarker-driven strategies and protocol refinements, into actionable workflows for cancer biology labs.

446 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page